新华保险11月12日公告，公司于2025年1月1日至2025年10月31日期间累计原保险保费收入为人民币 18,197,302万元，同比增长17%。 ...

★ 宏观动态 ★ 国家能源局：有序推动新能源供热供暖应用 《国家能源局关于促进新能源集成融合发展的指导意见》提出，有序推动新能源供热供暖应用。鼓励在纺织、 医药、造纸、食品加工等用热（冷）需求旺盛的产业园区，通过可再生能源电力供热、热泵供热（制冷）、光 伏光热一体化等方式，打造以新能源为主体的多能耦合综合供能站。摸清新能源供暖资源潜力，科学布局地热 能供暖，加强地热能梯级利用，因地制宜发展绿电直连等直接使用绿电的供暖模式，积极探索地热能、风光、 生物质及传统化石能源多热源互补高效利用，推动新能源供暖与既有供暖系统有机融合。发挥热力系统灵活调 节优势，推动新能源与热力系统联合优化调度运行，探索新能源供暖与岩土、水体等长周期储热技术耦合应 用。 财政部：2024年全国政府采购规模为33750.43亿元 财政部11月12日消息，2024年全国政府采购规模为33750.43亿元。其中，货物、工程、服务政府采购规模分别 为 7944.68亿元、13839.64亿元和11966.12亿元，占全国政府采购规模比例为23.54%、41.01%和35.45%。从组 织形式看，政府集中采购、部门集中采购、分散采购规模分别为766 ...

Group 1 - Longjian Co., Ltd. won a bid for a highway maintenance project in Heilongjiang with a contract value of 483 million yuan, accounting for 2.64% of the company's expected revenue for 2024 [1] - Transsion Holdings plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [1] - Good Home's controlling shareholder intends to reduce its stake by up to 2.7%, equivalent to no more than 39.4468 million shares [1][2] Group 2 - Xinhua Insurance reported a cumulative premium income of 181.973 billion yuan from January to October, representing a year-on-year growth of 17% [2][4] - Zhejiang Jiaokao is part of a consortium that plans to bid for a new urbanization project with an estimated total investment of 11.103 billion yuan [4] Group 3 - Changchun High-tech received approval for clinical trials of a vaccine for adolescents and adults [6] - XinNuoWei's application for the listing of Pertuzumab injection has been accepted, targeting HER2-positive breast cancer [8] - Dash Smart won a bid for an intelligent project at the new Huanggang Port inspection building, valued at 55.056 million yuan, which is 1.74% of its expected revenue for 2024 [8] Group 4 - Electronic City is involved in a lawsuit for debt recovery, with the amount in dispute estimated at 777 million yuan [9] - Haibo Technology signed a strategic cooperation agreement with CATL for a cumulative procurement of no less than 200 GWh of electricity from 2026 to 2028 [10] Group 5 - Renfu Pharmaceutical's HW231019 tablets have entered the second phase of clinical trials for postoperative pain relief [11] - Tonghua Dongbao received a drug registration certificate for Aspart Insulin injection from the Dominican Republic [11] Group 6 - Shaanxi Construction reported winning major projects worth a total of 1.016 billion yuan in October [12] - Fuzhou Environmental Protection plans to change its stock name to "Fuzhou Technology" [12] Group 7 - Panlong Pharmaceutical's gel patch for knee osteoarthritis has received approval for clinical trials [15] - Zhongyida's application for a specific stock issuance has been terminated by the Shanghai Stock Exchange [16] Group 8 - Zhizhong Home's controlling shareholder reduced its holdings of convertible bonds by 905,000 units, accounting for 13.51% of the total issued [19] - Haibo Co., Ltd. plans to establish a subsidiary with an investment of 1 billion yuan for high-end component projects [21] Group 9 - Caina Co. plans to use 57 million yuan of idle funds to purchase structured deposits [23] - Zhendong Pharmaceutical's new drug for acute ischemic stroke has entered the IIa phase of clinical trials [25] Group 10 - Weiman Sealing's overseas subsidiary plans to lease a factory in Saudi Arabia for 5 years at a total rent of approximately 54.039 million yuan [26] - Yiling Pharmaceutical's application for Memantine Hydrochloride has been approved for market entry [28] Group 11 - Dongfang Zhizao plans to acquire 70% of Saifu Machinery for 27.4887 million yuan [30] - JianKai Technology's actual controller intends to transfer 3% of the company's shares through inquiry [31] Group 12 - Rejing Bio plans to repurchase shares worth between 100 million and 200 million yuan [32] - Bangji Technology has decided to terminate a major asset restructuring project due to failure to reach an agreement [34] Group 13 - Huadong Pharmaceutical's application for the marketing license of a new drug has been accepted [36] - Zhonggu Logistics' shareholder plans to reduce its stake by up to 3% [38] Group 14 - Bohui Innovation's subsidiary received approval for a clinical trial of a vaccine for invasive infections [40] - Shannon Chip's shareholder pledged 0.27% of the company's shares for financing [42] Group 15 - Shanghai Petrochemical appointed a new general manager [44] - Jiaojian Co. plans to reduce the holdings of some directors and executives by up to 0.35% [46] Group 16 - Weiting Electric plans to raise no more than 300 million yuan through a private placement [47] - Zhongjin Irradiation plans to invest approximately 200 million yuan in an electronic accelerator manufacturing project [49] Group 17 - Tongxing Technology signed a framework agreement to invest 3.2 billion yuan in a sodium battery project [50] - Hongri Da plans to establish a subsidiary focused on semiconductor packaging [51] Group 18 - Shanghai Kaibao's new drug for acute ischemic stroke has received approval for clinical trials [53] - Yitong Century announced a change in its control structure, becoming a company without a controlling shareholder [55]

北京商报讯(记者李秀梅)11月12日，新华人寿保险股份有限公司(以下简称"新华保险（601336）")公 告，新华保险于2025年1月1日至2025年10月31日期间累计原保险保费收入为1819.73亿元，同比增长 17%。 ...

每经AI快讯，新华保险（601336）11月12日公告，公司2025年1至10月累计原保险保费收入1819.73亿 元，同比增长17%。 ...

证券之星消息，11月12日保险板块较上一交易日上涨2.26%，中国人保领涨。当日上证指数报收于 4000.14，下跌0.07%。深证成指报收于13240.62，下跌0.36%。保险板块个股涨跌见下表： | 代码 | 名称 | 主力净流入（元） | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入（元） | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 601318 中国平安 | | 2.73亿 | 3.03% | 8457.58万 | 0.94% | -3.57 Z | -3.97% | | 601336 | | 1.31亿 | 6.92% | 1920.93万 | 1.02% | -1.50 Z | -7.94% | | 601319 中国人保 | | 7018.68万 | 6.34% | -576.45万 | -0.52% | -6442.23万 | -5.82% | | 601628 中国人寿 | | 2882.84万 | 3.76% | 5416.29万 | 7.07% | -8299.13万 | -10.83 ...

公告表示，公司深入践行"以客户为中心"的战略导向，持续完善"保险+服务+投资"三端协同的高质量、 可持续发展模式，从产品、渠道、队伍、生态、运营、科技等多维度同步发力，深化体系化、专业化、 市场化改革，致力于公司规模价值双提升、品质结构双优化的高质量发展。 格隆汇11月12日丨新华保险(01336.HK)发布公告，公司于2025年1月1日至10月31日期间累计原保险保费 收入为人民币1819.73亿元，同比增长17%。 ...

公司深入践行"以客户为中心"的战略导向，持续完善"保险+服务+投资" 三端协同的高质量、可持续发展模式，从产品、渠道、队伍、生态、运营、科技 等多维度同步发力，深化体系化、专业化、市场化改革，致力于公司规模价值双 提升、品质结构双优化的高质量发展。 上述累计原保险保费收入数据未经审计，提请投资者注意。 | A股证券代码：601336 | A股证券简称：新华保险 编号：2025-061号 | | --- | --- | | H股证券代码： 01336 | H股证券简称：新华保险 | 新华人寿保险股份有限公司 保费收入公告 新华人寿保险股份有限公司董事会及全体董事保证本公告内容不存 在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担法律责任。 根据中华人民共和国财政部《企业会计准则第 25 号——原保险合同》（财 会〔2006〕3 号）及《保险合同相关会计处理规定》（财会〔2009〕15 号），新华 人寿保险股份有限公司（以下简称"公司"）于 2025 年 1 月 1 日至 2025 年 10 月 31 日期间累计原保险保费收入为人民币 18,197,302 万元，同比增长 17%。 ...

智通财经APP讯，新华保险(01336)公布，该公司于 2025 年 1 月 1 日至 2025 年 10 月 31 日期间累计原保 险保费收入为约人民币1819.73亿元，同比增长 17%。 ...

新华保险（601336）(01336)公布，该公司于2025年1月1日至2025年10月31日期间累计原保险保费收入 为约人民币1819.73亿元，同比增长17%。 ...